Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
Data from a prospective, observational cohort study analyzing 630 patients with polycythemia vera, essential thrombocytosis (ET), or primary myelofibrosis (PMF) demonstrated that males have inferior survival outcomes, compared with females and that they present more often with PMF, versus female patients who present more often with ET.
Blood (ASH Abstract)
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology
Frequency and Etiology of Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms
New England Journal of Medicine